Circulating HPV16 DNA may complement imaging assessment of early treatment efficacy in patients with HPV-positive oropharyngeal cancer

Tomasz W Rutkowski, Agnieszka M Mazurek, Mirosław Śnietura, Beata Hejduk, Maja Jędrzejewska, Barbara Bobek-Billewicz, Andrea d'Amico, Wojciech Pigłowski, Andrzej Wygoda, Krzysztof Składowski, Zofia Kołosza, Piotr Widłak, Tomasz W Rutkowski, Agnieszka M Mazurek, Mirosław Śnietura, Beata Hejduk, Maja Jędrzejewska, Barbara Bobek-Billewicz, Andrea d'Amico, Wojciech Pigłowski, Andrzej Wygoda, Krzysztof Składowski, Zofia Kołosza, Piotr Widłak

Abstract

Background: Early detection of treatment failure may improve clinical outcome and overall survival in patients with head and neck cancer after first-line treatment. Circulating cell-free HPV16 DNA (cfHPV16 DNA) was evaluated as a possible complementary marker to radiological assessment of early response in patients with HPV-related oropharyngeal cancer (OPC) after radiotherapy alone or combined with chemotherapy.

Methods: The study included 66 patients with HPV-related OPC receiving radical radiotherapy alone or in combination with chemotherapy. cfHPV16 DNA was assessed in the blood of all patients before treatment using TaqMan-based qPCR. Subsequent analysis of cfHPV16 DNA was performed 12 weeks after treatment completion, along with radiological assessment of early treatment results.

Results: Complete (CRR) and incomplete radiological response (IRR) was found in 43 (65%) and 23 (35%) patients respectively. cfHPV16 DNA was present in 5 (28%) patients with IRR, while only in 1 (4%) with CRR. Three of five patients with IRR that were positive for cfHPV16 DNA exhibited histopathologically confirmed local or regional treatment failure, and other two developed distant metastases. None of the patients with negative cfHPV16 DNA presented disease failure.

Conclusion: The post-treatment assessment of cfHPV16 DNA in patients with HPV-related OPC may be used as a complementary biomarker to conventional imaging-based examinations for early identification of treatment failure.

Keywords: Follow-up; HPV; Oropharyngeal cancer; Radiotherapy; Salvage; Treatment failure.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
The timeline for selected patients from IRR group who underwent intervention due to incomplete radiological response 12 weeks after treatment completion and/or presented cfHPV16 DNA at that time

References

    1. Pignon JP, le Maitre A, Maillard E, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92:4–14. doi: 10.1016/j.radonc.2009.04.014.
    1. Manikantan K, Khode S, Dwivedi RC, Palav R, Nutting CM, Rhys-Evans P, et al. Making sense of post-treatment surveillance in head and neck cancer: when and what of follow-up. Cancer Treat Rev. 2009;35:744–753. doi: 10.1016/j.ctrv.2009.08.007.
    1. Lell M, Baum U, Greess H, Nömayr A, Nkenke E, Koester M, et al. Head and neck tumors: imaging recurrent tumor and post-therapeutic changes with CT and MRI. Eur J Radiol. 2000;33:239–247. doi: 10.1016/S0720-048X(99)00120-5.
    1. Brakenhoff RH, Wagner S, Klussmann JP. Molecular patterns and biology of HPV-associated HNSCC. Recent Results Cancer Res. 2017;206:37–56. doi: 10.1007/978-3-319-43580-0_3.
    1. Cao H, Banh A, Kwok S, Shi X, Wu S, Krakow T, Khong B, et al. Quantitation of human papillomavirus DNA in plasma of oropharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys. 2012;82:351–358. doi: 10.1016/j.ijrobp.2011.05.061.
    1. Capone RB, Pai SI, Koch WM, Gillison ML, Danish HN, Westra WH, et al. Detection and quantitation of human papillomavirus (HPV) DNA in the sera of patients with HPV-associated head and neck squamous cell carcinoma. Clin Cancer Res. 2000;6:4171–4175.
    1. Dahlstrom KR, Li G, Hussey CS, Vo JT, Wei Q, Zhao C, Sturgis EM. Circulating human papillomavirus DNA as a marker for disease extent and recurrence among patients with oropharyngeal cancer. Cancer. 2015;121:3455–3456. doi: 10.1002/cncr.29538.
    1. Mazurek AM, Rutkowski T, Fiszer-Kierzkowska A, Małusecka E, Składowski K. Assessment of the total cfDNA and HPV16/18 detection in plasma samples of head and neck squamous cell carcinoma patients. Oral Oncol. 2016;54:36–41. doi: 10.1016/j.oraloncology.2015.12.002.
    1. Snietura M, Rutkowski T, Piglowski W, Hajduk A, Wygoda A, Skladowski K, et al. Human papillomavirus DNA in pharyngeal scrapes as a marker of HPV-related squamous cell cancer of the oropharynx. J Clin Virol. 2015;71:34–39. doi: 10.1016/j.jcv.2015.07.307.
    1. Snietura M, Piglowski W, Jaworska M, Mucha-Malecka A, Wozniak G, Lange D, Suwinski R. Impact of HPV infection on the clinical outcome of p-CAIR trial in head and neck cancer. Eur Arch Otorhinolaryngol. 2011;268:721–726. doi: 10.1007/s00405-010-1396-7.
    1. Kocjan BJ, Maver PJ, Hosnjak L, Zidar N, Odar K, Gale N, et al. Comparative evaluation of the Abbott RealTime High Risk HPV test and INNO-LiPA HPV Genotyping Extra test for detecting and identifying human papillomaviruses in archival tissue specimens of head and neck cancers. Acta Dermatovenerol Alp Pannonica Adriat. 2012;21:73–75.
    1. Mehanna H, Wong WL, McConkey CC, Rahman JK, Robinson M, Hartley AG, et al. PET-CT surveillance versus neck dissection in advanced head and neck cancer.; PET-NECK trial management group. N Engl J Med. 2016;374:1444–1454. doi: 10.1056/NEJMoa1514493.
    1. Vedrine PO, Thariat J, Hitier M, Janot F, Kaminsky MC, Makeieff M, French Groupe d’Etude des Tumeurs de la Tête et du Cou Group et al. Need for neck dissection after radiochemotherapy? A study of the French GETTEC Group. Laryngoscope. 2008;118:1775–1780. doi: 10.1097/MLG.0b013e31817f192a.
    1. Clavel S, Charron MP, Bélair M, Delouya G, Fortin B, Després P, et al. The role of computed tomography in the management of the neck after chemoradiotherapy in patients with head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2012;82:567–573. doi: 10.1016/j.ijrobp.2010.11.066.
    1. van der Putten L, van den Broek GB, de Bree R, van den Brekel MW, Balm AJ, Hoebers FJ, et al. Effectiveness of salvage selective and modified radical neck dissection for regional pathologic lymphadenopathy after chemoradiation. Head Neck. 2009;31:593–603. doi: 10.1002/hed.20987.
    1. Hamoir M, Ferlito A, Schmitz S, Hanin FX, Thariat J, Weynand B, et al. The role of neck dissection in the setting of chemoradiation therapy for head and neck squamous cell carcinoma with advanced neck disease. Oral Oncol. 2012;48:203–210. doi: 10.1016/j.oraloncology.2011.10.015.
    1. Shah S, Har-El G, Rosenfeld RM. Short-term and long-term quality of life after neck dissection. Head Neck. 2001;23:954–961. doi: 10.1002/hed.1138.
    1. Mrochem-Kwarciak J, Rutkowski T, Wygoda A, Deja R, Hajduk A, Składowski K. Early diagnosis of radiotherapy failure for patients with head and neck cancer: the role of biochemical markers. Tumori. 2017;104:273–279. doi: 10.5301/tj.5000639.
    1. Friedman JM, Stavas MJ, Cmelak AJ. Clinical and scientific impact of human papillomavirus on head and neck cancer. World J Clin Oncol. 2014;5:781–791. doi: 10.5306/wjco.v5.i4.781.
    1. Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008;100:261–269. doi: 10.1093/jnci/djn011.
    1. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24–35. doi: 10.1056/NEJMoa0912217.
    1. Jayaram SC, Muzaffar SJ, Ahmed I, Dhanda J, Paleri V, Mehanna H. Efficacy, outcomes, and complication rates of different surgical and nonsurgical treatment modalities for recurrent/residual oropharyngeal carcinoma: a systematic review and meta-analysis. Head Neck. 2016;38:1855–1861. doi: 10.1002/hed.24531.
    1. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29:4294–4301. doi: 10.1200/JCO.2011.36.4596.
    1. Ahn SM, Chan JY, Zhang Z, Wang H, Khan Z, Bishop JA, et al. Saliva and plasma quantitative polymerase chain reaction-based detection and surveillance of human papillomavirus-related head and neck cancer. JAMA Otolaryngol Head Neck Surg. 2014;140:846–854. doi: 10.1001/jamaoto.2014.1338.
    1. Lee JY, Garcia-Murillas I, Cutts RJ, De Castro DG, Grove L, Hurley T, et al. Predicting response to radical (chemo)radiotherapy with circulating HPV DNA in locally advanced head and neck squamous carcinoma. Br J Cancer. 2017;117:876–883. doi: 10.1038/bjc.2017.258.
    1. Mazurek AM, Rutkowski T, Śnietura M, Pigłowski W, Suwiński R, Składowski K. Detection of circulating HPV16 DNA as a biomarker in the blood of patients with human papillomavirus-positive oropharyngeal squamous cell carcinoma. Head Neck. 2019;41:632–641. doi: 10.1002/hed.25368.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner